Low exploratory: 1 nmol/kg subcutaneous (produces a measurable LH pulse within 30 minutes) Moderate support: 3 to 5 nmol/kg subcutaneous, daily or every other day, for 2 to 4 weeks Two forms exist: kisspeptin-54 (full-length, longer-acting, better studied in clinical trials) and kisspeptin-10 (C-terminal fragment, shorter-acting)
Igncio ABWT, Seixas-da-Silva IA, Silvestre DHS, Pinheiro MFC, Vaisman M, Conceio FL
Your goal determines protocol intensity and duration
Do not use in humans
Similar patterns of severe mitochondrial impairment have been extensively documented in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Clinical trials show meaningful weight loss and improved glycemic control